Sutureless 3F Enable Valve Replacement for Pure Aortic Regurgitation. Issue 11 (4th October 2015)

• Record Type: Journal Article
• Authors: Vola, Marco; Fuzellier, Jean‐François; Anselmi, Amedeo; Campisi, Salvatore; Haber, Benjamain; Isaaz, Karl; Gerbay, Antoine; Ruggieri, Vito Giovanni
• Is Part Of: Journal of cardiac surgery. Volume 30:Issue 11(2015:Nov.)
• Page Start: 796
• Page End: 800
• Publication Date: 2015-10-04
• Subjects: Heart -- Surgery -- Periodicals; 617.412005
• DOI: 10.1111/jocs.12647
• Languages: English
• ISSNs: 0886-0440

Abstract

Abstract: Background and Aim: We present our experience in the use of the sutureless valve in patients undergoing aortic valve replacement for pure aortic regurgitation. Methods: Out of 167 patients who underwent sutureless aortic valve implantation with a Medtronic 3f Enable prosthesis in our unit between March 2011 and February 2014, 12 (7.1%) received a sutureless valve for pure aortic regurgitation. Results: Mean age, logistic EuroSCORE, and left ventricular ejection fraction were 72 ± 5 years, 6.3 ± 2.9%, and 52.5 ± 15.3%, respectively. The sutureless valve could be successfully implanted in all cases; nine patients had a full sternotomy (associated coronary artery bypass graft in four cases and associated mitral surgery in five), one patient had a ministernotomy, and two had a thoracoscopic approach. Average cross‐clamping and cardiopulmonary bypass times were 90 ± 30 and 127 ± 51 minutes, respectively. At the outpatient echocardiography, average mean gradient was 10.54 ± 4.99 mmHg and a grade I–II paravalvular leakage (PVL) was detected in the first patient of the cohort (ministernotomy approach). At a mean follow‐up of 11.1 ± 5.5 months, average mean gradient was 9.75 ± 2.87 mmHg, no new PVL was detected, and the known PVL was stable. No pacemaker implantation was required. Conclusions: Implantation of the 3f Enable sutureless valve is technically possible with pure aortic regurgitation in selected patients. Multicenter investigations are necessary to assess the mid‐term benefits of such a device in this subset of patients.